Emergent BioSolutions Inc. (EBS Quick QuoteEBS - Free Report) was a big mover last session, as its shares rose almost 19% on the day. The move came after the company announced a new contract with the Centers for Disease Control and Prevention (CDC) and a separate deal with the Biomedical Advanced Research and Development Authority (BARDA), both to supply its anthrax vaccine BioThrax to the Strategic National Stockpile. This led to far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $26.27 to $31.40 in the past one-month time frame.

None of the estimates for this stock were revised over the past 30 days while the Zacks Consensus Estimate moved lower over the same time frame, suggesting there may be trouble down the road. So make sure to keep an eye on this stock going forward to see if this recent move higher can last.

Emergent BioSolutions carries a Zacks Rank #5 (Strong Sell) while its Earnings ESP is 0.00%.

EMERGENT BIOSOL Price

 

EMERGENT BIOSOL Price | EMERGENT BIOSOL Quote

A better-ranked stock in the medical-biomedical and genetics space is Athersys, Inc. , sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Is EBS going up? Or down? Predict to see what others think: Up or Down

Zacks' Top Investment Ideas for Long-Term Profit

How would you like to see our best recommendations to help you find today’s most promising long-term stocks? Starting now, you can look inside our portfolios featuring stocks under $10, income stocks, value investments and more. These picks, which have double and triple-digit profit potential, are rarely available to the public. But you can see them now. Click here >>